Table 6.

Approved Biosimilar and Follow-on Insulins in Europe, the United States, and China.

Follow-on insulin/biosimilar insulin	Manufacturer	Reference product	Type of insulin	Approvals
Abasaglar/Basaglar	Boehringer Ingelheim and Eli Lilly	Lantus	Insulin glargine	EMA 201471 US FDA 2015 as follow-on insulin 72
Semglee	Viatris/Biocon	Lantus	Insulin glargine	EMA 201874 US FDA 2020 as follow-on insulin US FDA 2021 as biosimilar 75
Admelog	Sanofi	Humalog	Insulin lispro	EMA 201776 US FDA 2017 as follow-on insulin 77
Sar-ASP	Sanofi	NovoRapid	Insulin aspart	EMA 2020 78
Kixelle	Viatris/Biocon	NovoRapid	Insulin aspart	EMA 2021 79

Abbreviations: EMA, European Medicines Agency; FDA, Food and Drug Administration.